Theravance Prices $98M IPO; Three Others Raise $85M Total Oct. 8, 2004 By Karen Carey The first full week of October proved to be a busy one for financings in the biotechnology world. (BioWorld Today)Read More
Vicuron Sells Shares, Gets $70.8M For Lead Products Oct. 1, 2004 By Karen Carey As it prepares regulatory filings for anidulafungin and dalbavancin, Vicuron Pharmaceuticals Inc. priced a public offering worth $70.8 million in gross proceeds. (BioWorld Today)Read More
